Monopar Therapeutics Inc. — Q1 2023 Form 10-Q
Business context and reporting period. This unaudited quarterly report covers the three months ended March 31, 2023. Monopar is a clinical-stage biopharmaceutical company with no approved products or product revenue. Its programs include Phase 1b camsirubicin, preclinical MNPR-101 radiopharmaceuticals and companion imaging agents, and early-stage MNPR-202.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $1.653 million | $1.678 million; down $25,000 |
| General and administrative expense | $872,000 | $779,000; up $93,000 |
| Total operating expense / operating loss | $2.525 million | $2.457 million / operating loss increased $68,000 |
| Interest income | $90,000 | $464; increase reflects Treasury and money-market interest |
| Net loss | $2.435 million | $2.457 million |
| Basic and diluted loss per share | $0.19 | $0.19 |
| Net cash used in operations | $2.271 million | $2.468 million |
| Cash and cash equivalents | $5.726 million at March 31 | $8.186 million at December 31, 2022 |
| Investments | $5.951 million at March 31 | $4.934 million at December 31, 2022 |
| Current liabilities / total liabilities | $2.888 million / $2.888 million | Total liabilities were $3.137 million at year-end |
Cash, cash equivalents and investments totaled approximately $11.7 million at March 31, 2023. Total assets were $11.832 million and stockholders’ equity was $8.945 million. The filing reports no debt. Operating cash outflow was partly offset by $804,798 in net financing cash inflow, mainly from at-the-market stock sales; investing cash outflow of $983,443 primarily reflected net purchases of U.S. Treasury bills. The company issued 244,392 shares under its sales agreement for net proceeds after fees and expenses of $807,338. Shares outstanding were 13,222,056 at March 31. Profit margins are not meaningful because the company had no revenue and reported operating losses.
Material changes and operating developments
- R&D expense declined slightly, mainly due to $120,000 lower personnel costs, partly offset by $79,000 higher Validive and camsirubicin trial and manufacturing costs. G&A expense increased mainly from salaries and benefits and accounting and audit fees.
- On March 27, 2023, Monopar discontinued the Validive Phase 2b/3 VOICE trial after the independent safety board determined the interim analysis did not meet the prespecified efficacy threshold: a 15% absolute difference in prevention of severe oral mucositis. The board reported no Validive-related safety concerns. The company expects site close-out costs in Q2 and no significant Validive expenses or future license or royalty obligations thereafter.
- The company was enrolling patients in the fifth dose cohort, 650 mg/m², of the camsirubicin Phase 1b trial. Management reported preliminary observations including no drug-related cardiotoxicity observed to date and one patient whose tumor became resectable after treatment; these are early trial observations, not established efficacy findings.
- Monopar and NorthStar are pursuing MNPR-101 radiopharmaceutical development. Management said they aim to initiate a first-in-human MNPR-101-Zr imaging study as early as year-end 2023, subject to development progress. MNPR-202 remains preclinical.
Outlook, risks and contingencies
- Management estimated available funds would support planned operations at least through June 2024, including expected camsirubicin Phase 1b topline results by year-end 2023 and advancement of MNPR-101 toward an initial human imaging study. Management cautioned that higher-than-expected camsirubicin dose escalation could defer topline results.
- The company expects to seek additional capital within the next 12 months. Future development depends on financing and/or collaboration arrangements; failure to secure adequate funding could require delaying, restructuring, or terminating programs. Equity financing could dilute shareholders, while collaborations could require sharing valuable rights.
- The Validive discontinuation was followed by a stock-price decline. The company warned that a continued decline could impair its ability to raise funds and affect operations.
- Key risks include clinical and regulatory uncertainty, trial enrollment and manufacturing delays, reliance on third-party providers, competition, intellectual-property and licensing risks, and inflation, geopolitical, economic-market, and COVID-19 effects on costs, operations, and financing.
- The filing reports no asserted legal claims. MNPR-101’s XOMA license includes potential clinical, regulatory, and sales milestones totaling up to $14.925 million if achieved; none had been reached by the reporting date.
Important facts for investors to verify
- Whether cash use and financing plans support the stated runway through June 2024, given continued operating losses and planned clinical spending.
- Timing and results of camsirubicin dose escalation, including whether management’s year-end 2023 topline-results expectation remains achievable.
- Progress, funding requirements, and timing for the proposed MNPR-101-Zr first-in-human imaging study.
- Final Validive close-out costs and confirmation that no further material license, royalty, or development obligations remain.
- Potential dilution from future equity sales and the terms and availability of alternative financing or strategic partnerships.